EirGen Pharma breast cancer product Eir-047 passes Fed and Fasted clinical trial in US

EirGen Pharma are pleased to announce that their oncology molecule "Eir-047" for early stage breast cancer treatment has successfully completed fed and fasted clinical studies in August 2008 to support licensing in the US market.

Technical Director Tom Brennan stated that "we are very pleased with this announcement as it shows our commitement to developing robust oncology products for global markets". Managing Director Patsy Carney stated that "this is another key milestone for the company and gives us a sound platform from which to launch our oncology franchise in key markets".

EirGen Pharma is a pharmaceutical company based in Waterford, Ireland. Using its purpose built high containment facility; the company specialises in the development, registration and manufacture of high potency solid dose products for global markets.